Table 4.
Summary of Previously Reported Outcomes of R-CHOP As Initial Therapy for MCL
| Reference | No. of Patients | Median Age (years) | Maintenance/Consolidation | Median PFS (months) |
|---|---|---|---|---|
| Howard et al3 | 40 | 55 | None | 17 |
| Lenz et al4* | 62 | 61 | Interferon | 19 |
| Rummel et al21 | 48 | 70 | None | 22 |
| Lacasce et al22* | 29 | 55 | None | 18 |
| Kluin-Nelemans et al23* | 280 | 70 | ||
| R-CHOP responders only | 79 | Rituximab | 56 | |
| 81 | Interferon | 24 | ||
| Smith et al, this article | 56 | 60 | RIT | 34† |
Abbreviations: MCL, mantle-cell lymphoma; PFS, progression-free survival; R-CHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; RIT, radioimmunotherapy.
*
Selected only R-CHOP treated, non–high-dose chemotherapy with autologous stem-cell support populations in these reports.
†
Reported as time to treatment failure.